Comparison
Amycretin vs. Petrelintide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
no data
Molecular weight
no data
no data
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Amycretin
Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.
Petrelintide
As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Amycretin and Petrelintide?
- Amycretin is classified as "Metabolic", while Petrelintide is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Amycretin or Petrelintide?
- The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Amycretin and Petrelintide in Germany and the United States?
- Germany: Amycretin — Unapproved, Petrelintide — Unapproved. United States: Amycretin — Unapproved, Petrelintide — Unapproved. These are factual summaries with source and review date on the individual pages.